Results 151 to 160 of about 16,276 (198)
, 2009 Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 1997
Clopidogrel is a thienopyridine that irreversibly inhibits platelet aggregation by selectively binding to adenylate cyclase-coupled ADP receptors on the platelet surface. In animal models, clopidogrel reduced the formation of both arterial and venous thrombi.
A J, Coukell, A, Markham
openaire +2 more sources
Clopidogrel is a thienopyridine that irreversibly inhibits platelet aggregation by selectively binding to adenylate cyclase-coupled ADP receptors on the platelet surface. In animal models, clopidogrel reduced the formation of both arterial and venous thrombi.
A J, Coukell, A, Markham
openaire +2 more sources
Expert Opinion on Drug Safety, 2010
Clopidogrel is an antiplatelet prodrug widely used in acute coronary syndromes and after intravascular stent placement. Acute or chronic use can cause bleeding, a major adverse effect, which can lead to drug discontinuation or noncompliance with therapy.The mechanism of action of clopidogrel, safety of different loading doses of clopidogrel, its use as
Kiran Kumar R, Mangalpally +1 more
openaire +2 more sources
Clopidogrel is an antiplatelet prodrug widely used in acute coronary syndromes and after intravascular stent placement. Acute or chronic use can cause bleeding, a major adverse effect, which can lead to drug discontinuation or noncompliance with therapy.The mechanism of action of clopidogrel, safety of different loading doses of clopidogrel, its use as
Kiran Kumar R, Mangalpally +1 more
openaire +2 more sources
Pharmacogenetics of Clopidogrel
Current Pharmaceutical Design, 2012Clopidogrel used in conjunction with aspirin has a central role in the treatment of patients with an acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI). The pharmacokinetic and pharmacodynamic responses to this drug are highly variable leaving up to one third of patients with inadequate platelet inhibition or high ...
Stephen A, O'Connor +5 more
openaire +2 more sources
American Journal of Therapeutics, 2010
Clopidogrel resistance is an emerging clinical scenario, as antiplatelet therapy has become the cornerstone of modern cardiovascular treatment. This leads to an increase in stent thromboses and recurrent ischemic events which add to the health care costs, and increased periprocedural morbidity and mortality.
Jaya Prakash, Sugunaraj +4 more
openaire +2 more sources
Clopidogrel resistance is an emerging clinical scenario, as antiplatelet therapy has become the cornerstone of modern cardiovascular treatment. This leads to an increase in stent thromboses and recurrent ischemic events which add to the health care costs, and increased periprocedural morbidity and mortality.
Jaya Prakash, Sugunaraj +4 more
openaire +2 more sources
Heart, Lung and Circulation, 2007
Clopidogrel resistance has been used as one of the terms employed in the literature to describe different degrees of ex vivo low platelet inhibition after clopidogrel administration. In addition to the diverse nomenclature, the characterisation of clopidogrel resistance has also been problematic because different authors have given different ...
Ernesto, Oqueli +2 more
openaire +2 more sources
Clopidogrel resistance has been used as one of the terms employed in the literature to describe different degrees of ex vivo low platelet inhibition after clopidogrel administration. In addition to the diverse nomenclature, the characterisation of clopidogrel resistance has also been problematic because different authors have given different ...
Ernesto, Oqueli +2 more
openaire +2 more sources
Clopidogrel resistance / Clopidogrel-Resistenz
LaboratoriumsMedizin, 2006Tobias Geisler, Meinrad Gawaz
openaire +1 more source